AZ Lynparza Head Hopes 2020 Will See PARP Inhibitor Treating Pancreatic Cancer
Executive Summary
AstraZeneca and Merck & Co hope Lynparza will soon have a third treatment indication after their PARP inhibitor became the first to demonstrate a benefit in germline BRCA-mutated metastatic pancreatic cancer, having hit targets in the Phase III POLO trial.
You may also be interested in...
Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.